[Central nervous system histoplasmosis]
- PMID: 19235462
[Central nervous system histoplasmosis]
Abstract
Central nervous system (CNS) histoplasmosis is one of the important endemic mycoses in America and Africa. Although the incidence of CNS histplasmosis in non-endemic areas is increasing, the diagnosis of isolated CNS histoplasmosis in these areas remains challenging. Since the diagnosis is often missed, the outcome of CNS histoplasmosis is occasionally poor. One of the important complications of this condition is hydrocephalus, which may be identified before meningitis is diagnosed. Antigen or serological tests are useful for the diagnosis of CNS histoplasmosis; however, it should be noted that false positive results may be obtained because of cross reactions due to infections by other fungi. Further, repeated culture with a large volume of cerebrospinal fluid is essential because of the low sensitivity of culture. Thus, it is recommended that tests for CNS histplasmosis be repeated, even if negative results are obtained initially. Liposomal amphotericin B is the usual initial therapy for CNS histoplasmosis. However, the rate of failure of initial treatment is high and relapse can occur in the next few years, which calls for careful management of patients with CNS histoplasmosis. Continued therapy with antifungal agents such as fluconazole or itraconazole is often required. We report a case of a patient with chronic meningitis in whom the tests for other causes were negative for about 10 years, and who was eventually diagnosed with CNS histoplasmosis. Treatment with fluconazole was initiated, and the patient's symptoms gradually improved. Further cerebrospinal fluid (CSF) analysis and brain computed tomography (CT) during the follow-up period of 2 years and 9 months did not reveal recurrence of meningitis or hydrocephalus, thereby indicating the successful treatment of CNS histoplasmosis with fluconazole. CNS histoplasmosis should always be included in the differential diagnoses of chronic meningitis in non-endemic areas even in the case of immunocompetent individuals.
Similar articles
-
Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection.J Infect Dis. 2002 Jun 15;185(12):1830-2. doi: 10.1086/340825. Epub 2002 May 31. J Infect Dis. 2002. PMID: 12085335
-
[Chronic central nervous system histoplasmosis in an immunocompetent patient].Neurologia. 2008 May;23(4):263-8. Neurologia. 2008. PMID: 18516749 Spanish.
-
The role of voriconazole in the treatment of central nervous system blastomycosis.Ann Pharmacother. 2009 Oct;43(10):1696-700. doi: 10.1345/aph.1M010. Epub 2009 Sep 1. Ann Pharmacother. 2009. PMID: 19724015 Review.
-
Neuroendoscopic diagnosis of central nervous system histoplasmosis with basilar arachnoiditis.World Neurosurg. 2012 Feb;77(2):399.E9-13. doi: 10.1016/j.wneu.2011.06.016. Epub 2011 Nov 7. World Neurosurg. 2012. PMID: 22120362
-
Diagnosis and management of central nervous system histoplasmosis.Clin Infect Dis. 2005 Mar 15;40(6):844-52. doi: 10.1086/427880. Epub 2005 Feb 16. Clin Infect Dis. 2005. PMID: 15736018 Review.
Cited by
-
Disseminated Central Nervous System Histoplasmosis: A Case Report.Cureus. 2019 Mar 12;11(3):e4238. doi: 10.7759/cureus.4238. Cureus. 2019. PMID: 31131162 Free PMC article.
-
Histoplasmosis with Deep CNS Involvement: Case Presentation with Discussion and Literature Review.J Neurol Surg Rep. 2015 Jul;76(1):e167-72. doi: 10.1055/s-0035-1554932. Epub 2015 Jun 26. J Neurol Surg Rep. 2015. PMID: 26251798 Free PMC article.
-
Neuroinfections caused by fungi.Infection. 2018 Aug;46(4):443-459. doi: 10.1007/s15010-018-1152-2. Epub 2018 May 21. Infection. 2018. PMID: 29785613 Free PMC article. Review.
-
Central nervous system histoplasmosis in an immunocompetent patient.J Neurol. 2010 Nov;257(11):1931-3. doi: 10.1007/s00415-010-5629-x. Epub 2010 Jun 22. J Neurol. 2010. PMID: 20567842 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical